
    
      The primary objective of the trial is to assess whether or not inhaled nitric oxide can
      decrease myocardial infarction (MI) size as a fraction of left ventricular size at 48-72
      hours in patients presenting with an ST segment elevation MI who undergo successful
      percutaneous coronary intervention.
    
  